Evolution
in progress
projects for partnering
We are looking for partners to further develop the projects in our pipeline and we are open to different business models: out-licensing, asset transfer into existing companies in exchange of equity, creation of new companies. More details on the projects can be discussed under CDA.
golgi pipeline
GPR120 AGONISTS
We are running lead optimization on two classes of novel agonists of the GPR120 receptor to mediate GLP-1 release and anti-inflammatory effects. The program is developable for both peripheral and CNS applications.
Main indications: neuroinflammation, epilepsy, metabolic disorders, liver injury and fibrosis.
Read short presentation
Want to read the full presentation?
Fill the form below and you will receive the full PDF in your inbox.
CX3CR1 AGONISTS
We are advancing in lead generation one class of small molecule agonists of the CX3CR1 receptor as potential therapeutics to regulate microglial homeostasis. The program is conducted as part of a research alliance with the MD Anderson Cancer Center’s Belfer Neurodegeneration Consortium (BNDC).
Main indications: multiple sclerosis, neurodegenerative diseases, age-related macular degeneration and other ophthalmological diseases.
Read short presentation
Want to read the full presentation?
Fill the form below and you will receive the full PDF in your inbox.
GPR65 MODULATORS
We are progressing into lead generation different classes of positive and negative modulators of the GPR65 receptor, to regulate inflammation in various diseases. The program is in collaboration with leadXpro, a leader in structure-based drug discovery and biophysical methods, providing the GPR65 cryo-EM structure and other assets.
Main indications: neuroinflammation, multiple sclerosis, Parkinson’s disease, fibrosis, cancer and inflammatory bowel disease.
Read short presentation
Want to read the full presentation?
Fill the form below and you will receive the full PDF in your inbox.
